White papers, narratives & perspectives

Rare disease conversations in Latin America need to move beyond awareness toward systemic solutions. Brazil, Chile, and Mexico have each built components of care architecture — but the region lacks a unified framework to connect these efforts and ensure equitable cross-border access.

What happens when semaglutide loses patent protection? Canada was first, but India provides the more revealing case study — immediate generic launches, a self-pay market, and no government GLP-1 reimbursement. Game-theoretic modelling forecasts how competitive dynamics unfold across four distinct market layers.

Two anti-amyloid therapies are now approved in the US — but most eligible patients never receive treatment. The bottleneck isn't drug efficacy. It's a systemic diagnosis-and-delivery failure across the entire patient pathway, from symptom recognition to infusion logistics.